Voya Investment Management LLC Decreases Stock Position in Intellia Therapeutics, Inc. $NTLA

Voya Investment Management LLC trimmed its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 42.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,456 shares of the company’s stock after selling 113,605 shares during the period. Voya Investment Management LLC’s holdings in Intellia Therapeutics were worth $2,650,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Marex Group plc purchased a new position in Intellia Therapeutics in the 2nd quarter valued at about $5,849,000. JPMorgan Chase & Co. increased its position in shares of Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after acquiring an additional 396,858 shares during the last quarter. Schroder Investment Management Group lifted its stake in shares of Intellia Therapeutics by 1,593.4% in the second quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after acquiring an additional 382,425 shares in the last quarter. Armistice Capital LLC purchased a new position in Intellia Therapeutics in the first quarter valued at about $2,588,000. Finally, Vestmark Advisory Solutions Inc. boosted its holdings in Intellia Therapeutics by 104.7% in the second quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock valued at $5,988,000 after purchasing an additional 326,460 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on NTLA. Barclays dropped their price objective on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Chardan Capital dropped their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Bank of America cut their price target on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Finally, Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a research report on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $18.43.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. The trade was a 3.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.10% of the company’s stock.

Intellia Therapeutics Trading Down 1.6%

NASDAQ:NTLA opened at $9.44 on Friday. The stock has a 50 day moving average of $11.48 and a 200-day moving average of $12.66. The firm has a market capitalization of $1.09 billion, a PE ratio of -2.21 and a beta of 2.13. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.10. The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business’s revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.34) EPS. As a group, analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.